Liqiang Xi

Staff Scientist

National Institutes of Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

The primary objective in multiply relapsed hairy cell leukemia and variant (HCL/HCLv) was to determine whether pentostatin-rituximab (DCFR) and bendamustine-rituximab (BR) each achieve an overall response rate (ORR) exceeding that historically achieved by rituximab alone (∼40%) in favor of 65%. Prospective data were unreported for either regimen. Fifty-six patients received 6 28-day cycles of rituximab (375 mg/m2, days 1 and 15) with either bendamustine (90 mg/m2, days 1 and 2) or pentostatin (4 mg/m2, days 1 and 15). Eligibility required ≥2 purine analogs, or 1 purine analog plus rituximab for response of <1 year to the initial purine analog. Although patients were assigned to either regimen through randomization to increase homogeneity of the 2 treatment groups, the DCFR arm had fewer previous purine analogs (P = .021) and lower baseline marrow HCL/HCLv infiltration (P = .013). ORRs for DCFR and BR were 93% (95% confidence intervals [CI], 83-102) and 86%, (95% CI, 73-99), respectively, exceeding 40% (P< .0001) for each group. Rates for complete remission (CR) and minimal residual disease-free CR and median progression-free survival (141 vs 50 months; HR, 0.63; 95% CI, 0.32-1.25) numerically favored DCFR, but that arm was significantly enriched with less previous purine analogs and marrow infiltration, each of which was associated post hoc with better response. Post hoc subgroup analysis, particularly for 41 patients with classic HCL, suggested any superiority of DCFR vs BR might apply to patients with more favorable disease. DCFR and BR were highly effective in multiply relapsed HCL/HCLv. Possible DCFR superiority was hypothesis-generating, given uneven baseline risks and trial design. This trial was registered at www.clinicaltrials.gov as #NCT01059786.

Year:

2026

Year:

2025

We found 20 patients with an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V600E. Fourteen had 1 non-V600E BRAF mutation and 6 had V600E with 1 (n = 5) or 2 (n = 1) non-V600E BRAF comutations. This study was registered at https://clinicaltrials.gov as #NCT01087333.

Year:

2025

Summary and list of detected and reported alterations by alteration type (CNV, SNV/Indel) and assay (both assays, Central Lab (CL) or Assay H only, Pilot Lab only). For both detected and reported variants, positive percent agreement (PPA) with Pilot Lab and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.

Year:

2025

Scatter plots of continuous copy number results obtained from Central Lab (CL) or assay H and Designated Lab (DL) assay. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is for variants detected by both assays but not reported by at least one assay, and orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.

Year:

2025

Purpose: NCI selected a network of Clinical Laboratory Improvement Amendments–certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms. Experimental Design: Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed for single-nucleotide variant, insertion and deletion, and copy-number variant classes. Results: We observed high concordance in variant detection between CL and DL for single-nucleotide variants and insertions and deletions [average positive agreement (APA) > 95.4% for all pairwise comparisons] but lower concordance for variant reporting after analysis pipeline filtering. We observed much higher agreement between CL and assays using amplification as the target enrichment method (84.2% 82%) except between CL and two assays (APA = 76.9% and 71.4%) due to differences in estimation of copy numbers. Notably, for all variants, differences in variant interpretation also contributed to reporting discrepancies. Conclusions: This study indicates that different NGS tumor profiling tests currently in widespread clinical use achieve high concordance between assays in variant detection. For variant reporting, observed discrepancies are mainly introduced during the bioinformatic analysis.

Year:

2025

Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.

Year:

2025

Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated. Cytogenetics results for all concordance study samples and gene amplification measurements using different techniques: NGS, ddPCR, microarray and FISH

Year:

2025

A, Scatter plot of continuous VAF results between Central Lab (CL) or assay H and Pilot Lab. B, Scatter plot of continuous CN results. The large plot focuses on copy numbers up to 50, while the small inset shows the full range of CNV. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is detected but not reported by Pilot Lab, while orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.

Year:

2025

Each worksheet shows all variants reported by a given Designated Laboratory, including those that are outside of the overlap region between the Central Assay and the Designated Laboratory Assay

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Collaborators (27)

Jean Donadieu

MD Ph D

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Hao-Wei Wang

Head, FLOW CYTOMETRY LABORATORY

National Cancer Institute

UNITED STATES
View details

Wenjuan Zhang

Assistant Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Noah Brown

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

Markku Miettinen

Senior Clinician, Head of Surgical Pathology

National Institutes of Health

UNITED STATES
View details

Irene Gullo

Professor Auxiliar Convidado

University of Porto

PORTUGAL
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Szabolcs Szelinger

Research Assistant Professor

Translational Genomics Research Institute

UNITED STATES
View details

Manoj Tyagi

Head of Bioinformatics Unit

National Institutes of Health

UNITED STATES
View details

Peining Li

Professor

Yale University School of Medicine

UNITED STATES
View details

Parth Anil Desai

Assistant Professor/Clinical Investigator

Fox Chase Cancer Center

UNITED STATES
View details

Christopher William Schultz

Assistant Professor

Temple University

UNITED STATES
View details

Elaine Jaffe

Head, Hematopathology Section

National Cancer Institute

UNITED STATES
View details

maxime battistella

Assistant professor

Université Paris Diderot

FRANCE
View details

Jean-François Emile

Université de Versailles Saint-Quentin-en-Yvelines

FRANCE
View details

Michelle Afkhami, MD

Chief and Professor, Division of Molecular Pathology and Therapy Biomarkers

City of Hope

UNITED STATES
View details

Mahesh Mansukhani

Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Neal Lindeman

Vice Chair, Molecular Pathology and Laboratory Medicine

Weill Cornell Medicine

UNITED STATES
View details

RAVINDRA KOLHE

Augusta University

UNITED STATES
View details

SHUBHANK GOYAL

The University of Texas Rio Grande Valley

UNITED STATES
View details

Eric Konnick

Associate Professor

University of Washington

UNITED STATES
View details

Svetlana Pack

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Jeremy Davis

Professor and Chief, Division of Surgical Oncology

University of Maryland School of Medicine

UNITED STATES
View details

Zenta Walther

Associate Professor

Yale University School of Medicine

UNITED STATES
View details

Theo Heller

National Institutes of Health

UNITED STATES
View details

William D Figg

Senior Investigator, Lab Chief, Associate Director

National Institutes of Health

UNITED STATES
View details